Brief: Takeda Pharmaceutical - Currently Assessing Amount Of Provision To Be Recognized In Group Earnings For FY Ended March 31
19/05/2026 02:27
May 19 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T: TAKEDA PROVIDES AN UPDATE REGARDING JURY VERDICT IN AMITIZA ANTITRUST LITIGATION IN U.S. AND RELATED REVISION TO FY2025 FINANCIAL RESULTS CURRENTLY ASSESSING AMOUNT OF PROVISION TO BE RECOGNIZED IN GROUP EARNINGS FOR FY ENDED MARCH 31, 2026 ONCE AMOUNT IS DETERMINED, WILL RECORD PROVISION AND REVISE FY2025/26 FINANCIAL STATEMENTS WITH TSE DO NOT EXPECT FY2026 FINANCIAL FORECAST TO BE MATERIALLY IMPACTED EXCEPT FOR ADJUSTED FREE CASH FLOW FORECAST, DEPENDING ON AMOUNT AND TIMING OF ANY PAYMENT Source text: ID:nTSqs83ead Further company coverage: 4502.T
Recent news on Takeda Pharmaceutical
See all newsTakeda launches sleep disorder pill in the US after DEA clearance removes final hurdle (updated)
Brief: Takeda's Orzeyful Available In U.S. By Prescription To Treat Narcolepsy Type 1 In Adults
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
Takeda Pharmaceutical Company Limited reports results for the quarter ended September 30 - Earnings Summary
Table: Takeda Pharmaceutical Company Limited -6-MTH group results (IFRS)